All data are presented as median values (interquartile range). Nonparametrical statistics was used throughout the study, Mann-Whitney U test for comparing independent groups, Spearman rank for correlation analysis and Wilcoxon signed-rank test for analysing dependent variables. A bivariate immune response variable was considered positive if higher than baseline for the given individual, and Fisher exact test were used for proportional group comparisons. p-values <0.05 were considered statistically significant. Two-tailed test were generally used unless paired tests had indicated a uni-directional change. Statistical analyses were done using Statistica software (Statsoft Inc.). The current trial shows the ability of the Vacc-5q peptides to elicit potent HIV-associated cellular immune responses not only in chronic HIV-patients stable on ART, but also in treatment-naïve patients with sustained viremia. Most patients in both study arms enhanced robust cellular immune responses both in vivo by DTH, and in vitro with overall similar response rates in the two groups. Anne-Marte Bakken Kran, Comparable Cellular Immune Responses in Patients with and without Antiretroviral Treatment after Immunization with HIV-1 P24, P17 and Tat Consensus Peptides (Vacc-5q)
Last date updated on September, 2024